BraTS Continuous Evaluation
Learn More Brain tumors are among the deadliest types of cancer. Specifically, glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma
Anti-PD1 Response Prediction Dream Challenge
LEARN MORE While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1 therapy,
CTD2 Chemosensitivity DREAM Challenge
Learn More The Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and
CTD^2 BeatAML DREAM Challenge
Learn More The goal of the Beat AML DREAM Challenge is to define patient subpopulations tailored to individual treatments by discovering (genomic
CTD^2 Pancancer Drug Activity DREAM Challenge
Learn More Over the course of two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive
Single-Cell Signaling in Breast Cancer DREAM Challenge
Learn More Signaling underlines nearly every cellular event. Individual cells, even if genetically identical, respond to perturbation in different ways. This underscores
NCI-CPTAC DREAM Proteogenomics
Learn More Cancer is driven by aberrations in the genome [1,2], and these alterations manifest themselves largely in the changes in the
Digital Mammography DREAM Challenge
Learn More The Digital Mammography DREAM Challenge will attempt to improve the predictive accuracy of digital mammography for the early detection of
Multiple Myeloma DREAM Challenge
Learn More Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on
ICGC-TCGA DREAM Somatic Mutation Calling – RNA Challenge
Learn More The ICGC-TCGA DREAM Somatic Mutation Calling - RNA Challenge (SMC-RNA) is an international effort to improve standard methods for identifying